Formulary Search Results for: INSULIN GLARGINE
6.1.1.2 Intermediate- and long-acting insulins - View Category
Restrictions:
Restricted to patients with type 1 diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin. In patients with type 2 diabetes it should be restricted to those who suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections.
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Prescribing Notes:
It is good practice to prescribe biosimilar insulins by brand name. The current preferred brand in NHSGGC is Semglee®
Please note: Insulin glargine is available in two strengths and caution should be taken in prescribing, dispensing and administration to ensure the correct strength is received.
Insulin glargine 300 units/ml (Toujeo®) is further restricted to use in patients where the use of high-strength insulin is appropriate.
6.1.2.6 GLP-1 agonists - View Category
Restrictions:
Restricted to initiation by Consultant Diabetologists for use in patients who are uncontrolled on basal insulin analogues (glycosylated haemoglobin [HbA1c] >7.5% [59mmol/mol]) and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin analogues.
Prescribing Notes:
Lixisenatide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
6.1.1.1 Short-acting insulins - View Category
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes and for use in patients where regular human soluble insulin is inappropriate.
6.1.1.1 Short-acting insulins - View Category
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Prescribing Notes:
Currently, only the 100 units/ml preparations have been considered and added to Formulary. Other strengths are currently non-Formulary
6.1.1.1 Short-acting insulins - View Category
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
6.1.1.1 Short-acting insulins - View Category
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
6.1.1.1 Short-acting insulins - View Category
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
6.1.1.2 Intermediate- and long-acting insulins - View Category
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes. Restricted to use in accordance with local guidance which includes information on preferred alternative options.
Prescribing Notes:
Note: Insulin degludec is available in two strengths and caution should be taken in prescribing, dispensing and administration to ensure the correct strength is received.
6.1.1.2 Intermediate- and long-acting insulins - View Category
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
6.1.1.2 Intermediate- and long-acting insulins - View Category
Restrictions:
Insulin detemir (Levemir®) is restricted to use in children, adolescent and adult patients with severe/ frequent nocturnal hypoglycaemia. Not for routine use in type 2 diabetes unless patients suffers from recurrent episodes of hypoglycaemia. Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.